FATI-유니콘뉴스

뉴스기사물 (10)

2024-05-25 00:06:33

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

DARMSTADT, GERMANY--(Business Wire / Korea Newswire)--Merck, a leading science and technology company, today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO)...

2024-04-12 00:00:11

Sintavia Announces $25M Expansion in Hollywood, Florida

HOLLYWOOD, FLA.--(Business Wire / Korea Newswire)--Sintavia, LLC, the world’s first all-digital aerospace component manufacturer, today announced its single largest expansion in facilities and equipment since 2019. The $25 million investment includes additional advanced manufacturing...

2024-03-22 12:03:17

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

OSAKA, JAPAN & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) for the treatment...

2024-03-18 00:06:29

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

BASEL, SWITZERLAND & BEIJING & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved...

2024-03-15 20:55:21

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

OSAKA, JAPAN & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients...

2024-03-10 13:39:44

Sysdig Rated #1 for CSPM in Gartner® “Voice of the Customer” Report

SAN FRANCISCO--(Business Wire / Korea Newswire)--Sysdig, the leader in cloud security powered by runtime insights, today announced that the company was named a Strong Performer - one of only two vendors to receive the...

2024-01-10 19:11:22

Kolmar BNH’s HemoHIM gets dual recognition for fatigue improvement, immune enhancement

SEOUL--(Korea Newswire)--Kolmar BNH, a Korean health supplement original development manufacturing (ODM), said the Ministry of Food and Drug Safety has recognized both fatigue improvement and immune enhancement capabilities for HemoHIM, a health-functional food developed...

2023-12-27 23:05:50

농정원, 식생활 트렌드 키워드 분석 결과 발표

농업산업생활식품 음료 세종--(뉴스와이어)--농림수산식품교육문화정보원(원장 이종순, 이하 농정원)이 ‘식생활 트렌드’를 주제로 온라인 언급량과 키워드를 분석한 ‘FATI(Farm Trend&Issue)’ 보고서 16호를 발표했다. ‘식생활 트렌드’ 관련 최근 4개년 정보량 추이 ...

2023-12-17 15:22:57

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, JAPAN & CAMBRIDGE, MASS--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of HYQVIA® [Immune Globulin Infusion...

2023-12-15 10:02:31

농정원, 농업·농촌 가치 키워드 분석결과 발표

경제신상품경제 동향조사연구농수산농업대전/충남 세종--(뉴스와이어)--농림수산식품교육문화정보원(원장 이종순, 이하 농정원)이 ‘농업 가치’를 주제로 온라인 언급량과 키워드를 분석한 ‘FATI(Farm Trend&Issue)’ 보고서 15호를 발표했다. ‘농업·농촌의 공익적 가치’ 관련 4개년 정보량 추이 ...

API